伏壁型組成和侵襲性腫瘤大小對第一期肺腺癌患者之長期預後之影響

10.6666/ClinMed.202407_94(1).0074

劉佳；黃建勝

肺腺癌（lung adenocarcinoma） ； 伏壁型組成（lepidic component） ； 侵襲性腫瘤大小

臨床醫學月刊

94卷1期（2024 / 07 / 26）

417 - 420

繁體中文

肺腺癌是非小細胞肺癌中最常見的類型。隨著低劑量電腦斷層掃描的廣泛應用，更多3公分以下的第一期肺腺癌被早期診斷。雖然病理分期都是第一期，不同的腫瘤經手術切除後，長期預後卻有很大的差異。分析臺北榮總的治療經驗，透過對1,049名第一期肺腺癌患者病理組織的回顧性分析，我們發現伏壁型組成（lepidic component）比例≥50%的病患者有較好的預後，而在伏壁型組成比例<50%的病例中，侵襲性腫瘤大小則成為了預後的重要指標。現行的腫瘤－淋巴結－轉移（TNM）腫瘤分期系統可能未能充分反映伏壁型成分較高腫瘤的長期預後。

1. Chen YJ, Roumeliotis TI, Chang YH, et al. Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression. Cell 2020;182:226-44 e17.
   連結：
2. National Lung Screening Trial Research T, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013;368:1980-91.
   連結：
3. Ye T, Deng L, Wang S, et al. Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype. J Thorac Oncol 2019;14:617-27.
   連結：
4. Detterbeck FC. The eighth edition TNM stage classification for lung cancer: What does it mean on main street? J Thorac Cardiovasc Surg 2018;155:356-59.
   連結：
5. Kadota K, Villena-Vargas J, Yoshizawa A, et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol 2014;38:448-60.
   連結：
6. Kameda K, Eguchi T, Lu S, et al. Implications of the Eighth Edition of the TNM Proposal: Invasive Versus Total Tumor Size for the T Descriptor in Pathologic Stage I-IIA Lung Adenocarcinoma. J Thorac Oncol 2018;13:1919-29.
   連結：
7. Travis WD, Brambilla E, Burke AP, et al. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol 2015;10:1240-42.
   連結：
8. Sasada S, Miyata Y, Mimae T, et al. Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma. Ann Thorac Surg 2015;1002079-86.
   連結：
9. Sasada S, Miyata Y, Mimae T, et al. Application of Lepidic Component Predominance to Adjuvant Chemotherapy with Oral Fluoropyrimidines for Stage I Lung Adenocarcinoma. Clin Lung Cancer 2016;17:433-40.
   連結：
10. Moon Y, Sung SW, Lee KY, et al. The importance of the lepidic component as a prognostic factor in stage I pulmonary adenocarcinoma. World J Surg Oncol 2016;14:37.
    連結：
11. Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2015;10:990-1003.
    連結：
12. Tsutani Y, Miyata Y, Mimae T, et al. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma. J Thorac Cardiovasc Surg 2013;146:580-5.
    連結：
13. Liu C, Wang LC, Chen HS, et al. Outcomes of patients with different lepidic percentage and tumor size of stage I lung adenocarcinoma. Thorac Cancer 2022;13:2005-13.
    連結：
14. Willner J, Narula N, Moreira AL. Updates on lung adenocarcinoma: invasive size, grading and STAS. Histopathology 2023.